MINDCURE’s unique approach to product development and investigation involves the elegance of our Five Spheres™ framework. We intend to find and deliver multipliers of value to shareholders that diversify our commercial outputs.
MINDCURE is focused on finding new ways to treat the profound distress of a world suffering from a mental health crisis. This is a tremendous opportunity to bring a new category of psychoactive and psychedelic treatments to market.
MINDCURE’s founding team and advisors have deep industry-specific experience in biotech, life sciences, new product discovery, research, technology, and entrepreneurship.
The company is uniquely situated in Canada, benefiting from a sophisticated investment community, world-class scientific professionals, and government leadership in research. Health Canada demonstrates that a science-first approach will pave the pathway for innovative research.
MINDCURE’s Five Spheres™
MINDCURE’s mission is to identify, develop, and commercialize products that enhance mental health and wellness, ease suffering, and increase productivity.
MINDCURE was formed as a response to a world suffering and in urgent need of effective treatments in the midst of a mental health crisis.
MINDCURE is exploring related and diverse therapeutic areas beyond psychiatry, which include therapeutics for neuropathic pain, neurodegenerative disease, and mental health.
Taken together, MINDCURE’s Five Spheres™, including research, discovery, clinical programs, technology, and GMP scale-up, will guide us in the adoption of psychedelic-assisted psychotherapy, regenerative medicine, and neuroscience. Beyond the physical and mental benefits, MINDCURE is determined to transform the ideas of today into the products of tomorrow that unify the mind and body in a world suffering from a mental health crisis.
Clinical Research Technology
Monitoring Psychoactive Therapy
MINDCURE is investigating technology that focuses on the connection between clinical patient‐trials that monitor, collect, or use patient information in order to assist in diagnosis and treatments.
Currently, most patients being treated for mental health concerns do not receive any meaningful data before and after therapy sessions. MINDCURE is investigating technology that could enable the collection of data between sessions. This would equip clinicians with additional patient feedback and data-driven insights into the efficacy of treatments therapy.
Manufacturing and Supplying Adaptogens
MINDCURE seeks to commercialize the therapeutic potential of nootropics, psychoactive products, and psychedelic substances that promote productivity and enhance mental health.
The first line of products that MINDCURE intends to launch are three types of organic mushroom nootropics. These products will be distributed under the following product names: MINDCURE Lion’s Mane Focus, MINDCURE Reishi Energy, and MINDCURE Turkey Tail Immunity. Each of these products will be available in powdered and capsule form.
Deliverying Psychoactive Therapies
MINDCURE is evaluating potential research programs, protocols, and supportive infrastructure to drive clinical research.
MINDCURE is investing in proprietary research programs, protocols, and support infrastructure for conducting clinical research. MINDCURE will examine the potential of mental health clinical trial protocols that may include psychoactive and psychedelic based substances, and investigate the ability to conduct clinical trials with Health Canada.
Investigating Custom Synthesis of Product Candidates and New Psychoactive Substances (NPS) or “Research Chemicals”
MINDCURE is evaluating the legal and commercial viability of psychedelic compounds, such as psilocybin, as part of its future product candidates.
MINDCURE’s product discovery sphere will investigate the potential of new discoveries and explore the therapeutic pathology and regenerative benefits of novel and traditional psychoactive chemical compounds in clinical studies. This investigation may include new and improved psychedelic-inspired product candidates ranging from proprietary new-psychedelic compounds to non‐psychedelics with medicinal properties.
Formulations & Supply
eGMP, API Manufacturing, and Supply
MINDCURE is interested in the potential of mental health clinical trial protocols that may include psychoactive and psychedelic-based substances.
MINDCURE will investigate the ability to conduct clinical trials under the supervision and guidance of Health Canada.
The process will comply with regulatory certifications and licensing within Canadian federal regulatory agencies (including Health Canada) and the US Federal regulatory agencies (including the FDA).
The importation of traditional and novel psychoactive substances into North America could be used to service clinical research programs and satisfy underserviced access to psychoactive pharmaceutical ingredients (API) for research.
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty six hundred dollars for Mind Cure Health Inc. current news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF Mind Cure Health Inc.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.